ACAD
40.1
-0.45
-1.11%
AEMD
8.65
-0.1
-1.14%
APRI
1.59
+0.03
+1.92%
ARNA
4.1
-0.09
-2.15%
ATEC
1.35
-0.01
-0.74%
CNAT
5.17
-0.19
-3.54%
CRXM
0.49
-0.01
-2.02%
CYTX
0.668
+0.008
+1.2119%
DXCM
68.65
-0.03
-0.04%
GNMK
9.05
+0.01
+0.11%
HALO
17.74
+0.29
+1.66%
ILMN
205.09
+0.09
+0.04%
INNV
0.147
-0.006
-3.9344%
INO
8.36
-0.47
-5.32%
ISCO
0.048
-0.002
-4.000%
ISIS
66.99
-0.77
-1.14%
LGND
89.17
-0.5
-0.56%
LPTN
0.298
-0.007
-2.2302%
MBVX
2.2
-0.09
-3.93%
MEIP
1.81
-0.06
-3.21%
MNOV
4
-0.05
-1.23%
MRTX
28.34
+1.53
+5.71%
MSTX
0.493
+0.003
+0.6735%
NBIX
42.3
-0.25
-0.59%
NUVA
48.48
+0.23
+0.48%
ONCS
0.233
0.00
0.00%
ONVO
4.67
+0.02
+0.43%
OREX
4.945
-0.065
-1.297%
OTIC
24.46
-0.4
-1.61%
QDEL
22.11
+0.27
+1.24%
RCPT
164.82
+3.17
+1.96%
RGLS
12.9
+0.05
+0.39%
RMD
57.42
+0.34
+0.60%
SCIE
0.016
-0.004
-21.2121%
SPHS
0.885
+0.04
+4.734%
SRNE
12.91
-0.03
-0.23%
TROV
10.96
+0.03
+0.27%
VICL
0.92
-0.01
-0.65%
VOLC
17.99
0.00
0.00%
ZGNX
1.39
-0.01
-0.71%
ACAD
40.1
-0.45
-1.11%
AEMD
8.65
-0.1
-1.14%
APRI
1.59
+0.03
+1.92%
ARNA
4.1
-0.09
-2.15%
ATEC
1.35
-0.01
-0.74%
CNAT
5.17
-0.19
-3.54%
CRXM
0.49
-0.01
-2.02%
CYTX
0.668
+0.008
+1.2119%
DXCM
68.65
-0.03
-0.04%
GNMK
9.05
+0.01
+0.11%
HALO
17.74
+0.29
+1.66%
ILMN
205.09
+0.09
+0.04%
INNV
0.147
-0.006
-3.9344%
INO
8.36
-0.47
-5.32%
ISCO
0.048
-0.002
-4.000%
ISIS
66.99
-0.77
-1.14%
LGND
89.17
-0.5
-0.56%
LPTN
0.298
-0.007
-2.2302%
MBVX
2.2
-0.09
-3.93%
MEIP
1.81
-0.06
-3.21%
MNOV
4
-0.05
-1.23%
MRTX
28.34
+1.53
+5.71%
MSTX
0.493
+0.003
+0.6735%
NBIX
42.3
-0.25
-0.59%
NUVA
48.48
+0.23
+0.48%
ONCS
0.233
0.00
0.00%
ONVO
4.67
+0.02
+0.43%
OREX
4.945
-0.065
-1.297%
OTIC
24.46
-0.4
-1.61%
QDEL
22.11
+0.27
+1.24%
RCPT
164.82
+3.17
+1.96%
RGLS
12.9
+0.05
+0.39%
RMD
57.42
+0.34
+0.60%
SCIE
0.016
-0.004
-21.2121%
SPHS
0.885
+0.04
+4.734%
SRNE
12.91
-0.03
-0.23%
TROV
10.96
+0.03
+0.27%
VICL
0.92
-0.01
-0.65%
VOLC
17.99
0.00
0.00%
ZGNX
1.39
-0.01
-0.71%
Home » John Finn Biography

John Finn Biography

Dr. Finn holds a B.S. in chemistry from Villanova University and a Ph.D. in organic chemistry from the University of Illinois. He spent the first ten years of his industrial career as doing optimization chemistry for American Cyanamid. In 1995, He moved to Synaptic Pharmaceutical as an associate director of medicinal chemistry at Synaptic Pharmaceutical focusing on drugs targeting novel GPCR targets. From 1998 to 2004, Dr. Finn held various leadership positions at Cubist Pharmaceuticals and Elitra Pharmaceuticals, two biotech companies focusing on novel antibacterial agents. Dr. Finn has served as the chief scientific officer of Trius since February 2007 and is a co-founder of our company. From July 2004 to February 2007, he served as the president.